How is synthetic lethality and CRISPR able to revolutionize the field of cancer treatment?
DOI:
https://doi.org/10.47611/jsrhs.v14i1.8539Keywords:
CRISPR, Cancer Treatment, Synthetic LethalityAbstract
Synthetic lethality is an emerging form of cancer treatment that has the potential to alter the field of cancer therapy. Current therapies, unlike novel gene therapies, are more toxic to the human body as well as being harmful to healthy cells. Treating cancer cells with synthetic lethality can avoid damaging the healthy cells by only targeting the mutated ones. Synthetic lethality can be initiated by CRISPR, a gene editing tool that can significantly increase the efficiency of the process. Furthermore, CRISPR screenings can scan for potential gene partners that can be exploited to trigger synthetic lethality in cancer cells. There are a number of clinical trials that use this form of treatment to target cancer cells. However, there are still some obstacles that must be solved to utilize this mechanism to its fullest extent, such as off-target effects from gene editing and gene targeting efficiency. Future research concerning synthetic lethality points toward simplifying the process and improving its accuracy. Nonetheless, despite its drawbacks, using CRISPR to initiate synthetic lethality is a novel and promising form of therapy that can revolutionize the field of cancer treatment.
Downloads
References or Bibliography
World Health Organization: WHO. Cancer. 3 Feb. 2022, www.who.int/news-room/fact-sheets/detail/cancer.
Worldwide Cancer Research. “Why Haven’t We Cured Cancer Yet?” Worldwide Cancer Research, 16 Nov. 2023, www.worldwidecancerresearch.org/news-opinion/2021/march/why-havent-we-cured-cancer-yet.
Oberstein, Paul E., and Kenneth P. Olive. “Pancreatic Cancer: Why Is It so Hard to Treat?” Therapeutic Advances in Gastroenterology, vol. 6, no. 4, Mar. 2013, pp. 321–37, doi:10.1177/1756283x13478680.
Corrie, Pippa G. “Cytotoxic Chemotherapy: Clinical Aspects.” Medicine, vol. 36, no. 1, Jan. 2008, pp. 24–28, doi:10.1016/j.mpmed.2007.10.012.
Cross, D., and J. K. Burmester. “Gene Therapy for Cancer Treatment: Past, Present and Future.” Clinical Medicine & Research, vol. 4, no. 3, Sept. 2006, pp. 218–27, doi:10.3121/cmr.4.3.218.
Douglas, Joanne T. “Cancer Gene Therapy.” Technology in Cancer Research & Treatment, vol. 2, no. 1, Feb. 2003, pp. 51–63, doi:10.1177/153303460300200107.
Wang, Dongrui, et al. “CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies.” Cancer Discovery, vol. 11, no. 5, Dec. 2020, pp. 1192–211, doi:10.1158/2159-8290.cd-20-1243.
Ding, Shuning, et al. “Single‐cell RNA Sequencing in Breast Cancer: Understanding Tumor Heterogeneity and Paving Roads to Individualized Therapy.” Cancer Communications, vol. 40, no. 8, July 2020, pp. 329–44, doi:10.1002/cac2.12078.
Topatana, Win, et al. “Advances in Synthetic Lethality for Cancer Therapy: Cellular Mechanism and Clinical Translation.” Journal of Hematology & Oncology, vol. 13, no. 1, Sept. 2020, doi:10.1186/s13045-020-00956-5.
Setton, Jeremy, et al. “Synthetic Lethality in Cancer Therapeutics: The Next Generation.” Cancer Discovery, vol. 11, no. 7, Apr. 2021, pp. 1626–35, doi:10.1158/2159-8290.cd-20-1503.
Kaelin, William G. “The Concept of Synthetic Lethality in the Context of Anticancer Therapy.” Nature Reviews. Cancer, vol. 5, no. 9, Aug. 2005, pp. 689–98, doi:10.1038/nrc1691.
Beijersbergen, Roderick L., et al. “Synthetic Lethality in Cancer Therapeutics.” Annual Review of Cancer Biology, vol. 1, no. 1, Mar. 2017, pp. 141–61, doi:10.1146/annurev-cancerbio-042016-073434.
Nijman, Sebastian M. B. “Synthetic Lethality: General Principles, Utility and Detection Using Genetic Screens in Human Cells.” FEBS Letters, vol. 585, no. 1, Nov. 2010, pp. 1–6, doi:10.1016/j.febslet.2010.11.024.
Murai, Junko, and Yves Pommier. “BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.” Cancer Research, vol. 83, no. 8, Apr. 2023, pp. 1173–74, doi:10.1158/0008-5472.can-23-0628.
Khan, Faheem Ahmed, et al. “CRISPR/Cas9 Therapeutics: A Cure for Cancer and Other Genetic Diseases.” Oncotarget, vol. 7, no. 32, May 2016, pp. 52541–52, doi:10.18632/oncotarget.9646.
Redman, Melody, et al. “What Is CRISPR/Cas9?” Archives of Disease in Childhood Education & Practice, vol. 101, no. 4, Apr. 2016, pp. 213–15, doi:10.1136/archdischild-2016-310459.
Gupta, Rajat M., and Kiran Musunuru. “Expanding the Genetic Editing Tool Kit: ZFNs, TALENs, and CRISPR-Cas9.” Journal of Clinical Investigation, vol. 124, no. 10, Oct. 2014, pp. 4154–61, doi:10.1172/jci72992.
Bansal, Roohi. “Limitations of ZFNs and TALENs (Part 18- CRISPR in Gene Editing and Beyond).” Medium, 10 May 2023, medium.com/biotechnology-by-tsb/limitations-of-zfns-and-talens-part-18-crispr-in-gene-editing-and-beyond-17593e183b8f.
“How CRISPR Is Changing Cancer Research and Treatment.” Cancer.gov, 27 July 2020, www.cancer.gov/news-events/cancer-currents-blog/2020/crispr-cancer-research-treatment.
Ishibashi, Airi, et al. “A Simple Method Using CRISPR-Cas9 to Knock-out Genes in Murine Cancerous Cell Lines.” Scientific Reports, vol. 10, no. 1, Dec. 2020, doi:10.1038/s41598-020-79303-0.
Dalvie, Neil C., et al. “Simplified Gene Knockout by CRISPR-Cas9-Induced Homologous Recombination.” ACS Synthetic Biology, vol. 11, no. 1, Dec. 2021, pp. 497–501, doi:10.1021/acssynbio.1c00194.
Wei, Xiaolong, et al. “Targeted CRISPR Screening Identifies PRMT5 as Synthetic Lethality Combinatorial Target With Gemcitabine in Pancreatic Cancer Cells.” Proceedings of the National Academy of Sciences of the United States of America, vol. 117, no. 45, 2020, pp. 28068–79. JSTOR, www.jstor.org/stable/26970706.
Bock, Christoph, et al. “High-content CRISPR Screening.” Nature Reviews Methods Primers, vol. 2, no. 1, Feb. 2022, doi:10.1038/s43586-021-00093-4.
He, Chenglong, et al. “CRISPR Screen in Cancer: Status Quo and Future Perspectives.” PubMed Central (PMC), 2021, www.ncbi.nlm.nih.gov/pmc/articles/PMC8085856.
Carroll, Dana. “Genome Engineering With Zinc-Finger Nucleases.” Genetics, vol. 188, no. 4, Aug. 2011, pp. 773–82, doi:10.1534/genetics.111.131433.
Joung, J. Keith, and Jeffry D. Sander. “TALENs: A Widely Applicable Technology for Targeted Genome Editing.” Nature Reviews Molecular Cell Biology, vol. 14, no. 1, Nov. 2012, pp. 49–55, doi:10.1038/nrm3486.
Ragupathi, Ashwin, et al. “Targeting the BRCA1/2 Deficient Cancer With PARP Inhibitors: Clinical Outcomes and Mechanistic Insights.” Frontiers in Cell and Developmental Biology, vol. 11, Mar. 2023, doi:10.3389/fcell.2023.1133472.
Robson, Mark, et al. “Olaparib for Metastatic Breast Cancer in Patients With a Germline BRCA Mutation.” New England Journal of Medicine, vol. 377, no. 6, Aug. 2017, pp. 523–33, doi:10.1056/nejmoa1706450.
Lukiw, Walter J. “Commentary: A Tribute to Dr. Paul Berg (1926–2023) American Biochemist, Nobel Laureate and Discoverer of Recombinant DNA Technology, Vaccine and Genetic Engineering.” Frontiers in Cell and Developmental Biology, vol. 11, May 2023, doi:10.3389/fcell.2023.1210530.
Rosenberg, Steven A., et al. “A New Approach to the Adoptive Immunotherapy of Cancer With Tumor-Infiltrating Lymphocytes.” Science, New Series, vol. 233, no. 4770, 1986, pp. 1318–21. JSTOR, www.jstor.org/stable/1697986.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Yixuan Liu
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
